Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Jazz Pharma Plc (JAZZ)
Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,581,282
  • Shares Outstanding, K 62,957
  • Annual Sales, $ 3,659 M
  • Annual Income, $ -224,060 K
  • 60-Month Beta 0.67
  • Price/Sales 2.06
  • Price/Cash Flow 5.51
  • Price/Book 2.20
Trade JAZZ with:

Options Overview Details

View History
  • Implied Volatility 35.95% ( +4.70%)
  • Historical Volatility 40.97%
  • IV Percentile 92%
  • IV Rank 30.53%
  • IV High 71.21% on 10/19/23
  • IV Low 20.45% on 08/30/23
  • Put/Call Vol Ratio 0.09
  • Today's Volume 58
  • Volume Avg (30-Day) 210
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 7,245
  • Open Int (30-Day) 7,616

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 4.33
  • Number of Estimates 8
  • High Estimate 4.96
  • Low Estimate 3.74
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +615.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.25 +8.24%
on 11/28/23
129.22 -6.81%
on 11/09/23
-7.82 (-6.10%)
since 11/08/23
3-Month
111.25 +8.24%
on 11/28/23
137.57 -12.47%
on 09/11/23
-15.98 (-11.72%)
since 09/08/23
52-Week
111.25 +8.24%
on 11/28/23
160.96 -25.19%
on 01/03/23
-29.65 (-19.76%)
since 12/08/22

Most Recent Stories

More News
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 1.5800 (-12.71%)
CARA : 1.2500 (+4.17%)
CRBP : 5.33 (-1.30%)
HRMY : 31.00 (-0.16%)
JAZZ : 120.42 (+0.73%)
3 Biotech Stocks That Could Be Millionaire Makers

Many biotech stocks offer exciting long-term growth prospects.

AAPL : 195.71 (+0.74%)
VRTX : 350.15 (-1.07%)
JAZZ : 120.42 (+0.73%)
JNJ : 154.42 (-0.63%)
CRSP : 64.54 (-8.08%)
MRNA : 80.32 (+0.46%)
AXSM : 70.18 (-0.07%)
3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases...

AMGN : 269.12 (-0.81%)
BMRN : 92.94 (-2.11%)
JAZZ : 120.42 (+0.73%)
VRTX : 350.15 (-1.07%)
3 No-Brainer Stocks to Buy With $200 Right Now

A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.

GOOGL : 134.99 (-1.42%)
GOOG : 136.64 (-1.31%)
JAZZ : 120.42 (+0.73%)
OKTA : 72.01 (+0.01%)
Jazz: Q3 Earnings Snapshot

Jazz: Q3 Earnings Snapshot

JAZZ : 120.42 (+0.73%)
Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company...

ALKS : 25.86 (-1.15%)
BIIB : 239.29 (+0.07%)
GILD : 79.02 (+1.24%)
JAZZ : 120.42 (+0.73%)
Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on... Regeneron...

GILD : 79.02 (+1.24%)
JAZZ : 120.42 (+0.73%)
OTSKY : 19.3500 (-1.93%)
REGN : 840.14 (-1.06%)
Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus...

ALKS : 25.86 (-1.15%)
AMGN : 269.12 (-0.81%)
GILD : 79.02 (+1.24%)
JAZZ : 120.42 (+0.73%)
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

DTCFF : 1.8500 (unch)
DTC.CN : 2.8000 (+27.27%)
JAZZ : 120.42 (+0.73%)
EXEL : 22.00 (+0.05%)
AMGN : 269.12 (-0.81%)
REGN : 840.14 (-1.06%)
Stocks Slump as Middle East Tensions Persist

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -1.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 4,604.37 (+0.41%)
SPY : 460.20 (+0.43%)
$DOWI : 36,247.87 (+0.36%)
DIA : 363.12 (+0.36%)
$IUXX : 16,084.69 (+0.39%)
QQQ : 392.17 (+0.45%)
RF : 17.44 (+1.10%)
CMA : 49.97 (+1.48%)
ZION : 38.93 (+1.43%)
FITB : 31.25 (+1.43%)
KEY : 13.26 (+1.14%)
USB : 40.43 (+1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 124.05
2nd Resistance Point 122.97
1st Resistance Point 121.69
Last Price 120.42
1st Support Level 119.33
2nd Support Level 118.25
3rd Support Level 116.97

See More

52-Week High 160.96
Fibonacci 61.8% 141.97
Fibonacci 50% 136.11
Fibonacci 38.2% 130.24
Last Price 120.42
52-Week Low 111.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar